CTOs on the Move

Clarvista Medical

www.clarvistamedical.com

 
ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Clarvista Medical raised $14M on 05/13/2015

Similar Companies

Taiho Oncology

Taiho Oncology, Inc. strives to make a positive contribution to society and the environment. We support our local communities through charitable endeavors, and we work proactively to protect the environment by minimizing the environmental impact in every aspect of our work-from research and development to production, distribution, marketing, and disposal. Furthermore, as a member of Otsuka Holdings, we are part of a group of companies that pursues initiatives that are shaped by mutual respect and open communication with all stakeholders, including customers and business partners in the countries and regions where we do business.

Q-One Biotech

Q-One Biotech is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Excelth Inc

Excelth Inc is a New Orleans, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Action Sport Physio

Action Sport Physio sports medicine clinics are renowned for the excellent results in the treatment of their patients rehabilitation needs. With a network of clinics across the province, our 400 multidisciplinary health professionals are available and accessible to provide the very best of quality care.